The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2021 | CANOPY-A: canakinumab for resected NSCLC
Alex Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, gives an overview of the Phase III CANOPY-A trial (NCT03447769) investigating the safety and efficacy of canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer (NSCLC). Canakinumab is a human monoclonal antibody therapy that targets interleukin-1 beta, and in this interview, Dr Spira describes the rationale for this trial-in-progress. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
